Drugs / HB0043
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07449156 | Mar → Oct 2026 expected | acne | Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06895499 | Mar 2025 → Jan 2026 overdue | hidradenitis suppurativa | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06999083 Comparator | Jun 2025 → Feb 2026 | — | Shanghai Huaota Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895499 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized IgG1 bispecific antibody targeting both IL-17A and IL-36R.” NCT06999083 ↗ |
| Route | Intravenous | “receive a low dose of HB0043 via intravenous infusion every two weeks” NCT06895499 ↗ |